Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Leading U.S. oncology brands based on revenue in 2016 (in million U.S. dollars)

Exclusive Premium Statistic

Top U.S. oncology products by revenue in 2016 This statistic describes the top pharmaceutical chemotherapy and targeted cancer products in the United States based on revenues during 2016. Novartis' Gleevec was among the top 10 cancer products in the United States, generating some 1.2 billion U.S. dollars in revenue. Cancer risk can increase due to internal or external factors, however, many types of cancers are preventable with a healthy diet, no smoking, and physical activity.
Show more
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Product (Company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Product (Company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

© Statista 2018

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic describes the top pharmaceutical chemotherapy and targeted cancer products in the United States based on revenues during 2016. Novartis' Gleevec was among the top 10 cancer products in the United States, generating some 1.2 billion U.S. dollars in revenue. Cancer risk can increase due to internal or external factors, however, many types of cancers are preventable with a healthy diet, no smoking, and physical activity.
Show more
Release date
August 2017
Region
United States
Survey time period
2016

Statista Accounts: Access All Statistics. Starting from $588 / Year

Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Top pharmaceutical drugs

All Information
in one Presentation

Top pharmaceutical drugs

Everything On "Top pharmaceutical drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Oncology"

  • Cancer facts
The most important statistics
  • Oncology market
The most important statistics
  • Companies
The most important statistics
  • Cancer drugs
The most important statistics
  • Research and development
The most important statistics
  • Immuno-oncology
The most important statistics
  • Treatment types
The most important statistics
  • Physicians and patients
The most important statistics
Statista for your company

Saves time and money: instant access to this and 1 million more statistics.
Access to dossiers, industry reports and many other studies.

Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.